Investigating the Combination therapy effect of Trastuzumab and Idarubicin on growth inhibition of HER2-positive breast cancer cells line (SK-BR-3)
Background & Objectives: Trastuzumab and Idarubicin (4-methyl-daunorubicin) are two anti-neoplasmic agents that are widely used in cancer therapy. Idarubicin is more lipophilic than its parent drugs such as daunorubicin, therefore it is absorbed more efficiently by the target cells. The main aim of...
Сохранить в:
| Главные авторы: | , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Fasa University of Medical Sciences
2017-11-01
|
| Серии: | Journal of Advanced Biomedical Sciences |
| Предметы: | |
| Online-ссылка: | http://jabs.fums.ac.ir/article-1-1270-en.pdf |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|